Summary

Our study uses an extensive, iterative research technique with a deviation minimization focus to produce the most precise estimates and forecasts. The organization divides and estimates quantitative parts of the market using a mix of top-down and bottom-up methodologies. Additionally, data triangulation—which examines the market from three angles—recurs frequently in all of our research studies.

On many fronts, raw market data is gathered and compiled. To make sure that only verified and authenticated sources are taken into consideration, data is constantly vetted. Furthermore, data is extracted from numerous reports within our repository and several well-known commercial databases. Understanding the entire value chain is crucial for a thorough understanding of the market, and we gather information from buyers, distributors, and suppliers of raw materials to make this process easier.

Trade journals, technical symposia, and surveys are good sources for technical concerns and trends. Technical information is also obtained with an emphasis on white space and freedom of movement from an intellectual property standpoint. Additionally gathered are industry factors pertaining to pricing patterns, constraints, and drivers. This means that a variety of original data are included in the material that is produced, and this data is further cross-validated and certified with public sources.
We use simulation models to produce our market estimates and forecasts. A distinct model is built specifically for every investigation. Data is supplied into the model and simultaneously examined for pricing patterns, application development, market dynamics, and technology landscape. These parameters are compared, and time series analysis, regression, and correlation are used to quantify their impact across the predicted period. Market forecasting is carried out using a mix of technical analysis, industry experience, and domain knowledge in addition to economic instruments.

Technological market models are utilized for long-term forecasting, while econometric models are typically employed for short-term forecasting. These are grounded in a combination of corporate principles, regulatory frameworks, economic outlooks, and the state of technology.

Pharmaceutical Drug Delivery Market based on Route of Administration:
• Topical drug delivery
• Other drug delivery
• Oral drug delivery
• Nasal drug delivery
• Ocular drug delivery
Pharmaceutical Drug Delivery Market based on Application:
• Cancer
• Diabetes
• Cardiovascular Diseases
• Others
Pharmaceutical Drug Delivery Market based on Geography:
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa

The number of patients in the healthcare system is growing as a result of the growing prevalence of chronic illnesses including diabetes, cancer, and other ailments throughout the world.

For example, the United States is expected to diagnose 1.9 million new instances of cancer in 2022, according to the American Cancer Society.
Furthermore, an increase in the prevalence of age-related conditions including rheumatoid arthritis, cardiovascular diseases, and others is being brought on by the aging population.

The patient population's need for individualized medications, vaccinations, and therapies is growing along with the prevalence and public awareness of infectious diseases and chronic ailments. In addition, the number of patients receiving treatment is fueled by rising per capita healthcare costs in both developed and developing nations. The demand for medications and therapies in the healthcare system is therefore expected to rise in response to the growing patient population and the development of healthcare facilities.

Major pharmaceutical firms are focusing more of their R&D efforts to create and expand their pipeline products as well as their portfolios due to the growing patient population and the increased demand for treatment and drugs for various therapeutic areas worldwide.

Before being put on the market, the medications and vaccines undergo extensive clinical testing to ensure their efficacy and safety. However, the clinical studies are only carried out with a limited number of candidates for short periods of time, and patients frequently experience specific adverse effects later on as a result of their age, immunological characteristics, and other considerations.

Additionally, the medicine recalls in the market damage the brand value of the market players harming their sales, customer connections, and reputation owing to mislabeling, possible contaminants, or subpar product manufacture.

Competitive analysis and profiles of the major players in the market, such as Bayer AG, Cipla Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Amgen Inc., Pfizer Inc., Sanofi. Major players have adopted acquisition as key developmental strategies to improve the product portfolio and gain strong foothold in the pharmaceutical drug delivery market.


• This report illustrates the most vital attributes of the Pharmaceutical Drug Delivery Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Pharmaceutical Drug Delivery Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Pharmaceutical Drug Delivery Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Pharmaceutical Drug Delivery Market.

ページTOPに戻る

Table of Contents

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Route of Administration: Market Size & Analysis
5.1. Overview
5.2. Topical drug delivery
5.3. Other drug delivery
5.4. Oral drug delivery
5.5. Nasal drug delivery
5.6. Ocular drug delivery
6. Application: Market Size & Analysis
6.1. Overview
6.2. Cancer
6.3. Diabetes
6.4. Cardiovascular Diseases
6.5. Others
7. Geography: Market Size & Analysis
7.1. Overview
7.2. North America (U.S., Mexico, Canada)
7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
7.5. Latin America (Brazil, Argentina)
7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
8. Competitive Landscape
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. Vendor Profiles
9.1. BAYER AG
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. BECTON, DICKINSON AND COMPANY
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. F. HOFFMANN-LA ROCHE AG
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. GLAXOSMITHKLINE PLC
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. JOHNSON & JOHNSON
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. MERCK & CO., INC.
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. NOVARTIS AG
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. 3M COMPANY
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. PFIZER INC.
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. SANOFI
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy

10. Analyst Opinion
11. Annexure
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 2. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE FOR TOPICAL DRUG DELIVERY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE FOR OTHER DRUG DELIVERY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE FOR ORAL DRUG DELIVERY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE FOR NASAL DRUG DELIVERY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE FOR OCULAR DRUG DELIVERY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 8. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE FOR CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE FOR DIABETES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE FOR CARDIOVASCULAR DISEASES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. PHARMACEUTICAL DRUG DELIVERY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 15. U.S PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 16. U.S PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 17. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 18. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 19. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 20. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 21. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 22. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 23. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 24. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 26. U.K PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 27. U.K PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 29. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 30. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 31. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 32. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 33. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 34. ROE PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 35. ROE PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 36. ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 37. ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 38. ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 39. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 40. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 41. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 42. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 43. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 44. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 45. REST OF APAC PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 46. REST OF APAC PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 47. LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 48. LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 49. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 50. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 51. ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 52. ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 53. MIDDLE EAST AND AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 54. MIDDLE EAST AND AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 55. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 56. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 57. UAE PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 58. UAE PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 59. REST OF MIDDLE EAST AND AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 60. REST OF MIDDLE EAST AND AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 61. BAYER AG: FINANCIALS
TABLE 62. BAYER AG: PRODUCTS & SERVICES
TABLE 63. BAYER AG: RECENT DEVELOPMENTS
TABLE 64. BECTON, DICKINSON AND COMPANY: FINANCIALS
TABLE 65. BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES
TABLE 66. BECTON, DICKINSON AND COMPANY: RECENT DEVELOPMENTS
TABLE 67. F. HOFFMANN-LA ROCHE AG: FINANCIALS
TABLE 68. F. HOFFMANN-LA ROCHE AG: PRODUCTS & SERVICES
TABLE 69. F. HOFFMANN-LA ROCHE AG: RECENT DEVELOPMENTS
TABLE 70. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 71. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 72. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 73. JOHNSON & JOHNSON: FINANCIALS
TABLE 74. JOHNSON & JOHNSON: PRODUCTS & SERVICES
TABLE 75. JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 76. MERCK & CO., INC.: FINANCIALS
TABLE 77. MERCK & CO., INC.: PRODUCTS & SERVICES
TABLE 78. MERCK & CO., INC.: RECENT DEVELOPMENTS
TABLE 79. NOVARTIS AG: FINANCIALS
TABLE 80. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 81. NOVARTIS AG: DEVELOPMENTS
TABLE 82. 3M COMPANY: FINANCIALS
TABLE 83. 3M COMPANY: PRODUCTS & SERVICES
TABLE 84. 3M COMPANY: RECENT DEVELOPMENTS
TABLE 85. PFIZER INC.: FINANCIALS
TABLE 86. PFIZER INC.: PRODUCTS & SERVICES
TABLE 87. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 88. SANOFI: FINANCIALS
TABLE 89. SANOFI: PRODUCTS & SERVICES
TABLE 90. SANOFI: RECENT DEVELOPMENTS